| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.42 | 2e-11 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.38 | 1e-07 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.26 | 0.0001 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.005 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.006 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |